Completed PHASE1 INTERVENTIONAL 2-arm NCT02039817

PK and PD Study of IDN-6556 in Subjects With Severe Renal Impairment and Matched Healthy Volunteers

An Open-Label Pharmacokinetic and Pharmacodynamic Study of a Single Dose of IDN-6556 in Subjects With Severe Renal Impairment and in Matched Healthy Volunteers

Sponsor: Conatus Pharmaceuticals Inc.

Conditions Kidney Disease Kidney Diseases Renal Impairment Renal Insufficiency

Interventions IDN-6556

Updated 8 times since 2017 Last updated: Dec 18, 2015 Started: Jan 31, 2014 Primary completion: Apr 30, 2014 Completion: Apr 30, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Kidney Disease and Kidney Diseases and is currently completed. Conatus Pharmaceuticals Inc. leads this study, which shows 8 recorded versions since 2014 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2023 — Jul 2024 [monthly]

Completed PHASE1
Dec 2022 — Jan 2023 [monthly]

Completed PHASE1
Jan 2021 — Dec 2022 [monthly]

Completed PHASE1

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Jan 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Conatus Pharmaceuticals Inc.

Data source: Conatus Pharmaceuticals Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• DeLand, United States
• Miami, United States